Puma Biotechnology Sees Q3 Sales $56.000M-$59.000M vs $60.500M Est
Puma Biotechnology (NASDAQ:PBYI) sees Q3 sales of $56.000 million-$59.000 million vs $60.500 million analyst estimate.
Read original at benzingaStocks · News reference
TD Cowen Maintains Hold on Puma Biotechnology, Raises Price Target to $6
TD Cowen analyst Marc Frahm maintains Puma Biotechnology (NASDAQ:PBYI) with a Hold and raises the price target from $5 to $6.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 7, 2026, 9:08 PM
- Checked
- Aug 7, 2026, 9:08 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Puma Biotechnology Raises FY2026 Sales Guidance from $222.000M-$229.000M to $224.000M-$231.000M vs $222.000M Est
Puma Biotechnology (NASDAQ:PBYI) raises FY2026 sales outlook from $222.000 million-$229.000 million to $224.000 million-$231.000 million vs $222.000 million estimate.
Read original at benzingaPuma Biotechnology Q2 Adj. EPS $0.19 Beats $0.04 Estimate, Sales $53.600M Beat $53.000M Estimate
Puma Biotechnology (NASDAQ:PBYI) reported quarterly earnings of $0.19 per share which beat the analyst consensus estimate of $0.04 by 375 percent. This is a 26.67 percent increase over earnings of $0.15 per share from
Read original at benzinga